Introduction {#Sec1}
============

Glutamate is the major excitatory neurotransmitter in the central nervous system (CNS). However, glutamatergic dysfunction/excitotoxicity is also widely believed to be involved in acute neurodegeneration (e.g., stroke and trauma), chronic neurodegeneration (e.g., Parkinson's disease, Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis---ALS) as well as in the symptomatology of numerous neurological and psychiatric disorders (e.g., epilepsy, Parkinson's disease, drug dependence, depression, anxiety and chronic pain) (Beal [@CR3]; Danysz and Parsons [@CR12]; Parsons et al. [@CR34]; Plaitakis et al. [@CR38]). Glutamate activates postsynaptic receptors, including ionotropic 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl) proprionate (AMPA) and *N*-methyl-[d]{.smallcaps}-aspartate (NMDA) receptors allowing the influx of Ca^2+^ ions---especially though the later and, in some cases, the former if edited GluR2 subunits are absent (Burnashev et al. [@CR7]). Although physiological elevations in intracellular Ca^2+^ are salient to normal cell functioning, the excessive or persistent influx of Ca^2+^ together with any Ca^2+^ release from intracellular compartments can overwhelm Ca^2+^-regulatory mechanisms and lead to cell death/excitotoxicity (Arundine and Tymianski [@CR1]; Danysz and Parsons [@CR12]; Krieger et al. [@CR22]; Muir et al. [@CR32]; Wenk et al. [@CR53]) and additionally to symptomatological disturbances, especially those involving pathological long-term plastic changes (e.g., chronic pain, drug abuse, epilepsy) (Arundine and Tymianski [@CR1]; Parsons et al. [@CR34], [@CR37]; Rogawski [@CR41]).

Data from animal models clearly suggest that modulation of glutamate function may be highly beneficial in the treatment of various neurodegenerative/neurological disorders in humans. Reduced glutamate tone may be achieved by different pharmacological interventions, two of which are especially important for the present study: first, antagonising/modulating post-synaptic receptors such as NMDA receptors and second, reducing glutamate release/or increasing uptake at pre-synaptic glutamatergic terminals.

Memantine is a clinically very well tolerated uncompetitive NMDA receptor antagonist (Chen et al. [@CR9]; Parsons et al. [@CR36], [@CR37]) and its protective effects have been shown in various models of acute and chronic neurodegeneration (Chen and Lipton [@CR8]; Chen et al. [@CR9]; Miguel-Hidalgo et al. [@CR30]; Wenk et al. [@CR54]; for review see Parsons et al. [@CR35], [@CR37]; Wenk et al. [@CR53]).

The application of so-called glutamate release inhibitors (GRIs) e.g., riluzole, lamotrigine, phosphophenytoin, gabapentin, pregabalin and lubeluzole may be another promising approach for the therapy of neurodegenerative diseases due to their mode of action: blockade of overactive glutamate transmission before it becomes neurotoxic or impedes neuronal discharges during seizures (Parsons et al. [@CR34]). Lamotrigine, for example is an anti-epileptic agent, whereas lubeluzole has been reported to be effective in patients with acute ischaemic stroke (Diener [@CR14]). Riluzole moderately slows disease progression in ALS patients (Bensimon et al. [@CR5]; Lacomblez et al. [@CR23]) and is currently the only approved drug for the treatment of ALS (Gordon [@CR19]; Miller et al. [@CR31]; Parsons and Danysz [@CR33]; Traynor et al. [@CR47]; Van Damme et al. [@CR49]).

The effects of riluzole on the glutamatergic system has been claimed to have both a pre- and postsynaptic locus, although the evidence for the former is more conclusive (MacIver et al. [@CR25]) for reviews see (Doble [@CR15]; Gordon [@CR19]; Miller et al. [@CR31]; Parsons and Danysz [@CR33]; Traynor et al. [@CR47]; Van Damme et al. [@CR49]). Both, in vitro and in vivo experiments have provided data indicating that riluzole has a higher potency to decrease NMDA-evoked responses than those mediated by non-NMDA receptors see (Mantz [@CR26]). It is widely accepted that the effects of rilzuole in ALS are, at best, moderate, and that a combination of drugs with different mechanisms of action might be a more promising therapeutic approach (Goodall and Morrison [@CR18]; McGeer and McGeer [@CR29]; Van Den Bosch et al. [@CR50]; Weiss et al. [@CR52]). However, it remains an open question whether there would still be a sufficient number of active NMDA receptors available during riluzole therapy to allow any additional effect of NMDA receptor antagonists if such compounds were administered in combination with riluzole in order to increase the treatment effect size in this very severe disorder.

When taken as an example indication, clinical monotherapy trials in ALS are probably not ethically justifiable due to the severity of this disease. Moreover, other glutamatergic combination therapies show promise in various animal models and can increase therapeutic effects whilst even reducing side effects---the best preclinical example might seem to be the combination of AMPA and NMDA receptor antagonists in epilepsy (Löscher et al. [@CR24]). In the present study we recorded evoked synaptic events in the CA1 region of murine hippocampal brain slices to determine the magnitude of the NMDA receptor contribution after the application of clinically relevant concentrations of riluzole.

Whilst the spinal cord is probably the main target tissue for the therapeutic effects of riluzole in ALS, we chose to use hippocampal slices as a model tissue relevant for the combined use of GRIs and NMDA receptor antagonists in numerous other indications where therapeutic efficacy of either treatment has been implicated by preclinical studies. NMDA receptors are highly expressed and play a pivotal role in glutamatergic transmission in this structure.

Material and methods {#Sec2}
====================

Brain slice preparation {#Sec3}
-----------------------

Sagital hippocampal slices (300 μm thick) were obtained from young adult (6--8 weeks) male mice that were anaesthetized with ether before decapitation. The experimental protocols were approved by the Ethical Committee on Animal Care and Use of the Government of Bavaria, Germany. The brain was rapidly removed, and slices were prepared in ice-cold Ringer solution using a vibroslicer (Microm, Walldorf, Germany). To minimize epileptiform activity the CA3 region was removed. All slices were placed in a holding chamber for at least 60 min and were then transferred to a submerged superfusing chamber for extracellular or whole-cell recordings. The flow rate of the solution through the chamber was 1.5 ml/min. The composition of the extracellular solution was 124 mM NaCl, 3 mM KCl, 26 mM NaHCO~3~, 2 mM CaCl~2~, 1 mM MgSO~4~, 10 mM [d]{.smallcaps}-glucose, and 1.25 mM NaH~2~PO~4~, bubbled with a 95% O~2~--5% CO~2~ mixture, and had a final pH of 7.3. All experiments were performed at room temperature.

Electrophysiological recording {#Sec4}
------------------------------

Extracellular recordings of field excitatory postsynaptic potentials (fEPSPs) were obtained from the dendritic region of the CA1 region of the hippocampus using glass micropipettes (1--2 MΩ) filled with superfusion solution.

Whole-cell recordings of excitatory postsynaptic currents (EPSCs) were obtained from somata of pyramidal neurons of the CA1 region by means of the blind patch clamp technique (Blanton et al. [@CR6]). The pipettes for whole-cell recording were filled with 130 mM CH~4~SO~3~, 130 mM CsOH, 0.05 mM EGTA, 5 mM HEPES, 1 mM MgCl~2~, 1 mM NaCl, and 5 mM QX314 and displayed resistances between 4.5 and 5 MΩ. To isolate glutamatergic dual component EPSCs, slices were perfused with picrotoxin (50 μM) and CGP 35348 (200 μM) to block γ-aminobutyric acid type A (GABA~A~) and type B (GABA~B~) receptors, respectively. Voltage-activated sodium and potassium channels were blocked by QX-314 and CsOH, applied intracellularly via the recording pipette. Currents were recorded with a switched voltage clamp amplifier (SEC-10L; NPI Electronics, Tamm, Germany) with switching frequencies of 80 kHz (25% duty cycle). Series resistance was monitored and continuously compensated in bridge mode. Neuronal input resistance was measured by injecting hyperpolarizing current pulses (300 ms, −10 mV).

EPSCs and fEPSPs were evoked by stimuli (0.033 Hz, 4--5 V, 20 μs), delivered via a bipolar tungsten electrodes insulated to the tip (5 μm tip diameter) and positioned in the Schaffer collateral--commissural pathway. To determine the magnitude of the NMDA receptor contribution to responses in the presence of riluzole (1 μM), we measured the charge/voltage transfer of the pharmacologically isolated dual component fEPSPs and EPSCs before and after the application of the competive NMDA receptor antagonist [d]{.smallcaps}-(-)-2-amino-5-phosphono-pentanoic acid (D-AP5; 100 μM)---this compound was chosen for these experiments because it is highly selective for NMDA receptors and shows rapid penetration into in vitro tissue slices and can also be rapidly washed out.

All experiments were performed at room temperature at a holding potential of −60 mV. The recordings were filtered (3 kHz) and the digitized (9 kHz) data were stored using a Power Macintosh G3 computer by a data acquisition and evaluation program (Pulse v. 8.5; Heka electronic GmbH, Lambrecht, Germany).

Statistical analysis was carried out using the Student's paired *t* test to compare the values of 10 min of a stable baseline (control), and after application of D-AP5. *P* \< 0.05 was considered as a significant difference. Data are presented as mean ± SEM.

Results {#Sec5}
=======

Effects of riluzole on synaptic transmission {#Sec6}
--------------------------------------------

In previous studies it has been shown that riluzole (5--20 μM) depresses glutamatergic synaptic responses in hippocampal slices and autaptic microculture neurons (MacIver et al. [@CR25]; Martin et al. [@CR28]; Prakriya and Mennerick [@CR39]) by pre-synaptic mechanisms such as the inhibition of voltage-activated sodium and/or N- and P/Q-type calcium channels (Huang et al. [@CR21]; Song et al. [@CR45]; Stefani et al. [@CR46]). Here, the amplitude and area under the curve (charge transfer) of glutamatergic dual component EPSCs, mediated by AMPA- and NMDA-receptors, were concentration-dependently reduced by the application of 1 μM and 10 μM riluzole (EPSC amplitude (1 μM) 88.5 ± 6.1%, (10 μM) 44.5 ± 13.9%; EPSC charge transfer (1 μM) 61.8 ± 7.3%, (10 μM) 49.2 ± 13.3%; *n* = 7; Fig. [1](#Fig1){ref-type="fig"}; *P* \< 0.05). Albeit with no clear concentration--response relationship, riluzole also affected the decay of the EPSC and reduced the time constant τ to 74.9 ± 8.5 and 83.6 ± 8.1% for 1 and 10 μM, respectively (Fig. [1](#Fig1){ref-type="fig"}). Both concentrations were significantly different to control (*P* \< 0.05) but not to each other (*P* \> 0.05).Fig. 1Riluzole, concentration-dependently reduced dual component EPSC charge and amplitude. **a**, **b** The application of 1 and 10 μM riluzole reduced EPSC amplitude. Representative traces are shown, original (*left*), normalized (*right*). Each traces in each figure recorded from one neuron, respectively. **c** Averaged data showing the effect of riluzole on EPSC amplitude, charge and time constant τ

Determination of the fraction of functional NMDA receptors after the application of riluzole (1 μM) {#Sec7}
---------------------------------------------------------------------------------------------------

For the measurement of AMPA and NMDA receptor components mediating a single-evoked response, we analysed the EPSC with different parameters and at different times following the stimulus (see Clark and Collingridge [@CR11]; Fig. [2](#Fig2){ref-type="fig"}a). This is illustrated by the current--voltage (I--V) relationship (Fig. [2](#Fig2){ref-type="fig"}a); the initial slope of the response (10--60% before the peak) is believed to be mainly mediated by AMPA receptors, whereas the amplitude of the later response (measured at 80 ms after the stimulus) displayed the expected NMDA receptor I--V function. As a further parameter, we assessed the charge transfer of the EPSC. After the EPSC responses were stable, either under control conditions or in the presence of riluzole (1 μM), D-AP5 (100 μM) was applied to ensure complete block of NMDA receptors. Under control conditions, D-AP5 reduced the initial slope and the response amplitude at 80 ms after the initial stimulation to 75.9 ± 12.7 and 46.6 ± 10.3%, respectively (*n* = 7; Fig. [2](#Fig2){ref-type="fig"}b, c, both *P* \< 0.05). During the application of riluzole, the D-AP5-induced effect on the "AMPA receptor" and the "NMDA receptor"-mediated components was similar and showed no statistically significant difference to experiments in the absence of riluzole. The initial slope was decreased to 77.8 ± 13.2% and the amplitude of the response at 80 ms was 37.2 ± 6.6% (*n* = 7; Fig. [2](#Fig2){ref-type="fig"}b, c, both *P* \< 0.05 compared to control but *P* \> 0.05 compared to riluzole). These results demonstrate that the proportion of active NMDA receptors was not affected by the presence of riluzole. However, the application of D-AP5 did indeed affect the amplitude of the dual component EPSC as well as the initial slope indicating that these parameters were clearly not exclusively mediated by AMPA receptor activation under our experimental conditions. Therefore, measurement of the charge transfer during the EPSC seemed to be a more precise parameter for the assessment of the magnitude of the contribution of NMDA receptor activation to this glutamateric synaptic signal. The charge transfer was calculated as the area under the curve of the EPSC. The decrease of the charge transfer of the EPSC with D-APV under control conditions did not differ from that in the presence of riluzole (control: 49.3 ± 11.7%; riluzole: 53.9 ± 5.1%; p \> 0.05, n = 7; Fig. [2](#Fig2){ref-type="fig"}c). In other words, riluzole did not affect the fraction of functional NMDA receptors contributing to the EPSC, neither when EPSC amplitude at 80 ms was assesssed (control: 54.5 ± 10.7%, riluzole: 63.4 ± 6.3%, *P* \> 0.05) nor when EPSC charge transfer was used as a quantifier (control: 50.5 ± 11.3%, riluzole: 46.2 ± 4.4%; *P* \> 0.05; Fig. [2](#Fig2){ref-type="fig"}d).Fig. 2The fraction of activated NMDA receptors under control conditions did not differ from those in the presence of riluzole. **a**, *left* Voltage-dependence of dual-component EPSCs. The *symbols* on the EPSC indicate where the AMPA and NMDA receptor-mediated synaptic components were measured; the slope between 10 and 60% of peak amplitude (*open circles*) and the amplitude at 80 ms following the stimulus (*closed circles*), respectively. **a**, *right* The corresponding current-voltage plot for the same cell. **b** Representative traces, original (*left*), normalized (*right*), showing the effect of D-AP5 (100 μM) on the EPSC responses with (*below*) and without (*top*) riluzole. **c** Average of all experiments: D-AP5 reduced the initial slope, the amplitude at a latency of 80 ms (left) and the charge of the EPSC (right). In the presence of riluzole, the D-AP5-induced effect on the AMPA receptor and the NMDA receptor component was similar and showed no statistically significant difference. **d** The proportion of active NMDA receptors was not attenuated in the presence of riluzole

In the next set of experiments we investigated the effects of riluzole on NMDA receptor contribution to synaptic potentials under somewhat more physiological conditions by performing extracellular field potential recordings without clamping the neurons at a specific membrane potential. As a measurement parameter we again calculated the fEPSP "voltage" transfer i.e. the area under the fEPSP curve. Riluzole (1 μM) per se decreased fEPSPs to 70.0 ± 5.9% (*n* = 8; Fig. [3](#Fig3){ref-type="fig"}a). When D-AP5 was applied, the "additional" change in the fEPSP evoked in control slices and those already exposed to riluzole showed no significant difference (fEPSP control: 73.5 ± 4.0%; riluzole: 81.2 ± 5.9%; *P* \> 0.05, *n* = 10; Fig. [3](#Fig3){ref-type="fig"}b). The fraction of activated NMDA receptors under control conditions therefore did not differ significantly from those in the presence of riluzole (fEPSP control: 30.0 ± 6.3%; riluzole: 26.5 ± 9.5%; *P* \> 0.05, *n* = 10; Fig. [3](#Fig3){ref-type="fig"}c).Fig. 3Extracellular recordings, without clamping the neurons, demonstrating similar results for riluzole on the contribution of NMDA receptors to the synaptic signal. As a measurement parameter we calculated the fEPSP charge. **a** Riluzole (1 μM) per se decreased fEPSP charge. **b** When D-AP5 was applied, the charge of the fEPSP evoked in control slices and those already exposed to riluzole (1 μM) showed no significant difference. **c** The fraction of activated NMDA receptors under control conditions did not differ from those in the presence of riluzole (1 μM)

Discussion {#Sec8}
==========

Memantine is approved for the therapy of moderate to severe Alzheimer's disease, but preclinical data indicate high therapeutic potential in many other diseases related to neurodegeneration (Parsons et al. [@CR35]; Rammes et al. [@CR40]; Wenk et al. [@CR53]). Riluzole is the only medication approved for the treatment of ALS and has been registered as a neuroprotective agent in several countries. On the other hand, riluzole has also been considered for therapeutic use in dementia and epilepsy (Doble [@CR15]; Gordon [@CR19]; Miller et al. [@CR31]; Parsons and Danysz [@CR33]; Van Damme et al. [@CR49]). Lamotrigine, gabapentin and the related pregabalin are registered for therapy in epilepsy (Rogawski [@CR41]; Zipp et al. [@CR56]) and phosphophenytoin is in phase II trials for stroke and ischaemia. In other words, in some CNS disorders, treatment with NMDA receptor antagonists might have to be in combination with other anti-glutamatergic agents---the best example of which would seem to be with riluzole in ALS (Goodall and Morrison [@CR18]; McGeer and McGeer [@CR29]; Van Den Bosch et al. [@CR50]; Weiss et al. [@CR52]).

It is therefore important to consider whether there would still be a sufficient number of active NMDA receptors to allow for any additional effects of an NMDA receptor antagonist with such combinations. Furthermore, in vitro and in vivo experiments have shown that riluzole has a higher potency to decrease the NMDA-evoked responses than that of non-NMDA receptors (see Mantz [@CR26]). Under such assumptions it might be concievable that the contribution of NMDA receptors underlying the dual component EPSC is significantly reduced in the presence of a GRI like riluzole.

In the present study, we demonstrated that the fraction of activated NMDA receptors during synaptic transmission to CA1 hippocampal neurons remained constant in the presence of the glutamate release inhibitor riluzole, which would indicate that additional effects would indeed be possible with an NMDA receptor antagonist during combination therapy.

Despite extensive studies, the precise mechanism of action of riluzole remains elusive. However, effects on voltage-activated Na^+^ channels (Benoit and Escande [@CR4]), background K^+^-channels (Duprat et al. [@CR16]), GABA uptake ((Mantz et al. [@CR27])) and voltage-activated Ca^2+^-channels (Huang et al. [@CR21]) have been suggested. Nontheless, riluzole clearly decreases the synaptic release of glutamate (Cheramy et al. [@CR10]; Martin et al. [@CR28]; Umemiya and Berger [@CR48]) and this effect is probably secondary to inhibition of voltage-activated Na^+^ channels (Doble [@CR15]; MacIver et al. [@CR25]; Yokoo et al. [@CR55]). Other recent findings indicate that riluzole not only decreases glutamate release, but also enhances glutamate uptake (Azbill et al. [@CR2]; Frizzo et al. [@CR17]). Interestingly, this effect was reported for concentrations reached under standard clinical conditions (Frizzo et al. [@CR17]), similar to those used in the present study.

Whatever, the MoA on glutamate release/uptake, such effects agree well with the results of the present study in which riluzole concentration-dependently reduced isolated dual-component EPSCs in CA1 neurons.

At synapses of CA1 pyramidal neurons, where glutamate is rapidly cleared from the synaptic cleft, the decay time of synaptic currents is determined primarily by the deactivation time constants of AMPA and NMDA receptors (Silver et al. [@CR44]). This is believed to be the main factor shaping the decay of EPSCs at cortical synapses (Hestrin [@CR20]). Although measurements at a holding potential of −60 mV normally provide the best separation of AMPA and NMDA receptor-mediated components of a dual component EPSCs (Clark and Collingridge [@CR11]), in the present experiments, the application of D-AP5 also affected both the amplitude of the dual component EPSC and also the initial slope indicating that these parameters were not exclusively associated with AMPA receptor activation. As such, the measurement of changes in the charge transfer of the EPSC in the presence of D-APV was deemed to be the most precise parameter for the assessment of the magnitude of NMDA receptor contribution to the synaptic signals recorded in the present experiments. These results were confirmed under more physiological conditions, when recording extracellulary from a population of neurons without clamping the membrane potential.

However, in the present experiments, riluzole affected both EPSC amplitude and charge transfer but had little selective effect on deactivation time. Moreover, measuring either the EPSC amplitude at a post-stimulus time of 80 ms or the charge transfer of pharmacologically isolated dual component EPSCs before and after the application of the NMDA receptor antagonist D-AP5 demonstrated that the fraction of activated NMDA receptors under control conditions did not differ from those in the presence of riluzole.

There is compelling evidence that abnormal activation of NMDA receptors and NMDA receptor-mediated excitotoxicity is involved in many CNS disorders (Rothstein [@CR42]; Shaw and Ince [@CR43]; Wenk et al. [@CR53]). Consequently, the NMDA receptor antagonist memantine has been shown to have therapeutic potential in preclinical models of various neurodegenerative diseases and shows clear clinical symptomatic improvement in Alzheimer′s disease (Danysz and Parsons [@CR13]; Parsons et al. [@CR35], [@CR37]). Another promising approach to ameliorate glutamatergic dysfunction might be the use of memantine in combination with selective inhibitors of glutamate release to gain additional therapeutic benefits and further reduce possible side effects. GRIs show therapeutic limitations; however, e.g., although riluzole has been shown to prolong the survival of motor neuron in ALS, its effects on the progression of disease are not consistent (Bensimon et al. [@CR5]; Lacomblez et al. [@CR23]). The combination of riluzole with NMDA receptor antagonists may therefore be more clinically useful in ALS patients to prolong neural survival (Goodall and Morrison [@CR18]; McGeer and McGeer [@CR29]; Van Den Bosch et al. [@CR50]; Weiss et al. [@CR52]). In fact, memantine has been shown to have therapeutic effects in a mouse model of ALS (Wang and Zhang, [@CR51]). Furthermore, memantine also shows antiepileptic activity (Parsons et al. [@CR35]) which might be useful in combination with gabapentin or pregabalin, two further modulators of synaptic release, particularly of glutamate, through direct actions on release machinery (Rogawski [@CR41]).

The results of the present study clearly demonstrates that NMDA receptors may be a valid pharmacological target during treatment with glutamate release inhibitors.
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